GlassScriptPhysician profile
Katie Davis
NPI 1669903084
$8,821.40
in general payments reported to CMS, 2019-2025
46 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,611 · 2022: $1,589 · 2023: $1,952 · 2024: $2,055 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,620.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,175.15 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $910.86 | 2021-2025 | |
| Corcept Therapeutics | $701.83 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $626.83 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $622.44 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $578.68 | 2021-2025 | Repatha, Evenity, Otezla |
| Astellas Pharma US INC | $425.82 | 2021-2023 | Veozah |
| Pfizer INC. | $395.54 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $375.56 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $330.06 | 2021-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.67 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $260.40 | 2021-2025 | Verquvo, Lagevrio, Belsomra |
| Daiichi Sankyo INC. | $215.02 | 2021-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.44 | 2021-2024 | Xifaxan, Trulance |
| Aurinia Pharma U.S., INC. | $127.02 | 2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $123.52 | 2021 | |
| Alkermes, INC. | $120.00 | 2024 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $119.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $117.63 | 2021-2024 | |
| Lilly USA, LLC | $109.06 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $95.47 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $75.64 | 2022-2023 | Ongentys, Ingrezza |
| Abbott Laboratories | $73.60 | 2021-2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $69.28 | 2021 | |
| Electromed, INC. | $68.25 | 2022 | |
| Exact Sciences Corporation | $65.91 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $64.57 | 2022-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $54.42 | 2023-2024 | Eliquis |
| Ucb, INC. | $49.11 | 2023-2024 | Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.85 | 2021-2023 | Jardiance, Synjardy |
| Medtronic, INC. | $34.18 | 2023 | Abre |
| Boston Scientific Corporation | $33.57 | 2022-2024 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $30.56 | 2021-2025 | Takhzyro |
| Lundbeck LLC | $30.20 | 2024-2025 | Rexulti |
| Eisai INC. | $29.25 | 2021 | |
| Aimmune Therapeutics, INC. | $21.51 | 2024 | |
| Scilex Pharmaceuticals INC. | $21.09 | 2022 | |
| Amarin Pharma, INC. | $20.27 | 2021 | |
| Neurelis, INC. | $19.24 | 2023 | Valtoco |
| Smith+Nephew, INC. | $18.91 | 2022 | |
| Corium, LLC | $17.74 | 2023 | Azstarys |
| Ferring Pharmaceuticals INC. | $17.26 | 2023 | Rebyota |
| Sanofi-Aventis U.S. LLC | $16.74 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.00 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $13.87 | 2022 | |
| Biogen, INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.